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E1A
E4orf6Human parvovirus B19 (B19V) DNA is highly prevalent in endothelial cells lining up intramyocardial
arterioles and postcapillary venules of patients with chronic myocarditis and cardiomyopathies. We
addressed the question of a possible stimulation of B19V gene expression in endothelial cells by infection with
adenoviruses. Adenovirus infection led to a strong augmentation of B19V structural and nonstructural
proteins in individual endothelial cells infected with B19V or transfected with an infectious B19V genome.
Transactivation was mostly mediated at the level of transcription and not due to adenovirus-mediated
induction of second-strand synthesis from the single-stranded parvoviral genome. The main adenoviral
functions required were E1A and E4orf6, which displayed synergistic effects. Furthermore, a limited B19V
genome replication could be demonstrated in endothelial cells and adenovirus infection induced the
appearance of putative dimeric replication intermediates. Thus the almost complete block in B19V gene
expression seen in endothelial cells can be abrogated by infection with other viruses.r Biotechnology, University of
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Human parvovirus B19 (B19V), a member of the genus Erythrovirus
in the family Parvoviridae, shows a very narrow cell and tissue tropism
with erythroid progenitor cells (EPCs) in the bone marrow or the fetal
liver as themain sites of viral replication (Ozawa et al., 1986; Srivastava
and Lu, 1988). Some of the main clinical manifestations of B19V
infection like transient aplastic crisis in patients with chronic hemolytic
anemia, pure red-cell aplasia due to persistent infection in immuno-
compromised patients, or hydrops fetalis after transplacental transmis-
sion are a direct consequence of the cytotoxic effects of B19V on EPCs
(Anderson et al., 1985). Recently, B19V has also been associated withacute or chronic myocarditis (Bock et al., 2010; Klingel et al., 2004). In a
screen for the presence of viral infections in endomyocardial biopsies
from patients with idiopathic dilated cardiomyopathy (DCM), B19V
DNA could be detected in more than half of the cases, often in
combination with other viruses such as human herpes virus 6 (HHV-6)
or adenoviruses (Kuhl et al., 2005). A high prevalence of cardiac B19V
infection was found in patients with isolated left ventricular diastolic
dysfunction and coexisting endothelial dysfunction (Tschope et al.,
2005). Both in acute B19V-induced myocarditis and in inﬂammatory
DCM (DCMi), the viral DNA was detected by in situ hybridization in the
endothelial cells of small intramyocardial arterioles and postcapillary
venules (Klingel et al., 2004).
The B19V viral particles with a diameter of about 25 nm consist of
the two capsid proteins VP1 and VP2 and harbor a small, linear, single-
stranded DNA genome of 5.6 kb (Heegaard and Brown, 2002). The
genome comprises two large open reading frames (ORFs) with a
single nonstructural protein (NS1) encoded by the ORF in the left half
and VP1/VP2 encoded by the ORF in the right side of the genome. The
ORFs are ﬂanked by two identical inverted terminal repeats (ITRs) of
383 nucleotides (nt), which serve as origins of DNA replication
(Cotmore and Tattersall, 2005) and also contain cis-acting sequences
involved in the regulation of the only functional B19V promoter at
Fig. 1. Stimulation of B19V capsid protein expression in B19V infected endothelial cells by super-infection with different adenovirus subtypes. (A–C) EA.hy926 cells were infected with
B19V puriﬁed from a human serum at a multiplicity of 1 × 104 genome equivalents per cell for 24 h, followed either by (A) mock infection or super-infection with either (B) adenovirus
subtype 2 (Ad2) or (C) adenovirus subtype 5 (Ad5), both atMOIs of 10, for 2 h. Forty-eight hours later, cells were assayed by immunoﬂuorescence analysis for B19VVP1/2 and adenoviral
E1A expression. Positions of VP1/VP2 positive cells and the corresponding positions in the E1A staining and themerge are indicated by arrows. (D) EA.hy926 cellswere infectedwith B19V
and eithermock-infectedor super-infectedwithAd2orAd5 as describedabove. Seventy-twohours later, B19VVP1/VP2mRNA levelswerequantiﬁedby real-timeRT-PCR. VP1/VP2mRNA
levels are indicated as relative levels with the value obtained in the absence of adenovirus super-infection set to 1. The data are presented as mean±standard error of mean (S.E.M.).
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52 T. Pozzuto et al. / Virology 411 (2011) 50–64map position 6, called p6. At least 12 different mRNAs are transcribed
from the B19V genome through alternative splicing and the use of two
different polyadenylation sites (Ozawa et al., 1987; Yoto et al., 2006).Fig. 2. Infectionwith adenovirus subtypes 2 and 5 stimulates B19Vprotein expression in endoth
cells as indicatedwere transfectedwith SalI linearized pB19-M20 plasmid. Forty-eight hours lat
as indicated. In the right panel, transfection efﬁciencywasmonitoredwith plasmid pGFP expres
cellswere transfectedwith SalI linearizedpB19-M20plasmid and additionally super-infectedw
by immunoﬂuorescence analysis for adenoviral E1A expression and B19V (B) VP1/2 or (C) N
positions in the E1A staining and the merge are indicated by arrows.The tropism of B19V for erythroid progenitor cells is regulated at
different levels. One of the major determinants is the distribution of
the primary B19V receptor, the blood-group P antigen (Brown et al.,elial cells transfectedwith an infectious B19Vplasmid construct. (A) EA.hy926 cells or 293
er cells were assayed by immunoﬂuorescence analysis for B19VNS1 and VP1/2 expression
sing the green ﬂuorescent protein under control of the CMVpromoter. (B and C) EA.hy926
ith Ad2 or Ad5 as described in the legend to Fig. 1. Forty-eighthours later cellswere assayed
S1 protein expression. Positions of VP1/VP2 or NS1 positive cells and the corresponding
53T. Pozzuto et al. / Virology 411 (2011) 50–641993), and the reported co-receptors integrin α5ß1 (Weigel-Kelley
et al., 2003) and Ku80 antigen (Munakata et al., 2005). However, P
antigen was detected not only on EPCs, but also on a variety of other
cell types including primary endothelial cells from umbilical cord
blood (HUVEC) (Weigel-Kelley et al., 2001). In line with these data,
experimental infection of HUVEC (Zakrzewska et al., 2005) with
detection of NS1 mRNA and small amounts of VP mRNAs has been
reported. Low expression levels of B19V gene products in endothelial
cells are probably a result of the low p6 promoter activity in the1.0E+01
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length VP transcript maturation as demonstrated for other non-
permissive cells (Liu et al., 1992; Ponnazhagan et al., 1996). The
preferential polyadenylation at the proximal site, which mainly
generates transcripts encoding the NS1 protein and the so-called
7.5 kDa protein, may be overcome by forced replication of the viral
genome through heterologous systems in some non-permissive cells
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54 T. Pozzuto et al. / Virology 411 (2011) 50–64Recently it was shown that the block in B19V DNA replication in
the non-permissive 293 cell line could be overcome by infection with
adenovirus or by complementation of the constitutively expressed
E1A and E1B genes with the E2a, E4orf6 and VA-RNA adenoviral
functions (Guan et al., 2009). Furthermore, infectious B19V particles
were produced in the presence of these ﬁve adenoviral functions at a
level comparable to that in the semi-permissive UT7/Epo-S1 cell line.
Intriguingly, the adenoviral functions required for B19V DNA
replication and the production of infectious particles in 293 cells
correspond to those identiﬁed as necessary for the productive
infection cycle of the helper-dependent AAVs.
In view of the high prevalence of B19V in endomyocardial biopsies
from patients with chronicmyocarditis and chronic cardiomyopathies
it was the aim of our study to assess a possible activation of B19V gene
expression in endothelial cells by infection with other viruses.
Adenovirus was chosen as a model system because of its well-
characterized helper functions for the closely related Dependovirus
genus of parvoviruses, the AAV and its ability to infect endothelial
cells.
Results
Adenovirus co-infection stimulates parvoviral capsid protein expression
in B19V infected endothelial cells
In initial experiments, the endothelial hybrid cell line EA.hy926
was infected with B19V obtained from sera of infected individuals and
cells were super-infectedwith adenovirus subtype 2 (Ad2) or subtype
5 (Ad5), respectively. B19V gene expression was monitored by VP1/2
immunoﬂuorescence analysis 48 h post-infection. Whereas only very
faint and infrequent signals for VP1/2 could be detected in the absence
of adenovirus (Fig. 1A), strong staining for VP1/2 expression was
detected in individual cells in the presence of either Ad2 or Ad5
(Fig. 1B and C, left columns). Since the adenoviral E1A protein acts as
transactivator for the other adenoviral early functions and a variety of
heterologous viral and cellular promoters, we performed additional
staining with an antibody directed against this protein and observed
two different principal phenotypes. In some cells, strong simultaneous
expression of both adenoviral E1A and the B19V capsid proteins
was found (Fig. 1B and C, upper right panels). However, other cells
displayed B19V VP1/2 expression without detectable amounts of E1A
(Fig. 1B and C, lower panels). Even at high multiplicities of infection
(MOI) for both B19V and adenovirus, detectable B19V VP1/2
expression was limited to a very small subset of cells, despite the
high percentage (N80%) of adenovirus-infected EA.hy926 cells
obtained in control experiments with a GFP-expressing adenoviral
vector (data not shown). Adenovirus-mediated transactivation of
B19V capsid gene expression was not exclusively monitored at the
single cell level, but also in quantitative RT-PCR of VP1/2 transcripts. A
13- to 14-fold increase in VP1/2 mRNA levels was seen after co-
infection with Ad2 or Ad5 (Fig. 1D). From these data it cannot be
concluded unambiguously, whether the increase in VP1/2 expression
is due to a modest stimulation in all B19V infected cells or to a strong
activation in a subset of infected cells. However, the results of the
immunoﬂuorescence experiments seem to favor the latter possibility.Fig. 4. Identiﬁcation of the adenoviral functions involved in transactivation of the B19V p6
promoter constructs used in the experiments and the corresponding region in the B19V gen
grey shadings; the luciferase (luc) ORF is shown in white. The B19V nucleotide positions are
binding sites (NS1-BE) are indicated by black bars. Lower part: EA.hy926 cells were transfe
additionally infected with Ad5. Forty-eight hours post-transfection luciferase activities were
construct p6-luc in the absence of adenoviral functions set to 1. (B) HCMV-driven NS1 prot
cells were transfected with SalI linearized DNA from pB19-M20 or the NS1-negative pB19-M
plasmid pKEX-NS1 as labeled above the lanes. Hirt DNAs (6 μg) isolated 40 hours post-tran
hybridization probe. Arrows indicate the positions of putative monomeric (RFM) and dimer
(C and D) and primary human endothelial cells (E and F) from the coronary artery (HCAEC
indicated adenoviral functions. Forty-eight hours post-transfection luciferase activities were
absence of adenoviral functions set as 1. The data are presented as mean±S.E.M.Adenovirus stimulates B19V expression at a level succeeding viral entry
and uncoating
As demonstrated above, only a small subset of endothelial cells
expressed detectable B19V capsid protein levels following B19V
infection and subsequent adenovirus super-infection. To exclude the
possibility that this conﬁnement was due to a limited uptake of B19V,
an infectious B19V genome, pB19-M20 (Zhi et al., 2004) was used for
further investigations. Transfection of a transcription-competent
double-stranded B19V DNA eliminates possible effects of adenovirus
on B19V entry, intracellular release or uncoating. In line with the
results of the B19V infection experiments, no VP1/VP2 expression
could be detected by immunoﬂuorescence analysis after pB19-M20
transfection of EA.hy926 cells. The B19V nonstructural protein NS1,
which in contrast to the capsid proteins does not rely on splicing and
read-through at the internal polyadenylation site, was also not
detectable (Fig. 2A, upper left panels). Control transfections with a
GFP expression plasmid showed that this lack of B19V protein
expression was not caused by limitations in transfection efﬁciency,
which was in the range of 40–60% positive cells (Fig. 2A, upper right
panel). In 293 cells used as controls, a distinct VP signal could be
observed in a relatively large subset of cells and an even higher
fraction of cells expressed the NS1 protein (Fig. 2A, lower left panels).
Since both cell lines showed comparable transfection efﬁciencies with
the GFP control plasmid (Fig. 2A, right panel), the conclusion seems
warranted that the constitutive expression of the adenoviral E1A
and/or E1B genes in 293 cells stimulates B19V gene expression. In
line with these considerations, super-infection of pB19-M20 trans-
fected EA.hy926 cells with either Ad2 or Ad5 also led to strong NS1
and VP1/2 signals in individual cells with a generally higher number
of NS1 than VP1/2 positive cells (Fig. 2B and C, upper panels). As
observed after B19V/adenovirus co-infection (compare Fig. 1), B19V
NS1 and VP1/2 expression was not limited to E1A positive cells, but
was also seen in many cases in E1A negative cells (Fig. 2B and C,
middle and lower panels). Both the level of adenovirus-induced
transactivation of B19V gene expression and the conﬁnement of
detectable protein expression levels to a very small subset of
endothelial cells were similar as in the initial co-infection experi-
ments. Thus they seem to be mediated by viral and cellular factors
involved in the regulation of gene expression from a transcription-
competent double-stranded DNA form of the B19V genome, and not
by factors limiting B19V cellular entry or uncoating.
Adenovirus-mediated transactivation of the B19V p6 promoter from a
single-stranded DNA template
The B19V genome contains a single functional promoter at map
position 6 (p6), which drives the expression of all B19V gene products
including the nonstructural protein (NS1) and the capsid proteins VP1
and VP2. To elucidate the mechanisms of adenovirus-mediated
transactivation of B19V capsid protein expression in endothelial
cells, the impact of adenovirus infection on the activity of the core p6
promoter containing B19V nucleotides 381–615 (nucleotide num-
bering according to the J35 isolate of the B19V genome) was studied
with the help of luciferase reporter constructs. To more closely mimicpromoter in endothelial cell lines. (A) Upper part: Schematic representation of the p6
ome. The B19V left ITR, the p6 promoter and the NS1 ORF are represented by different
indicated above the bars with numbering according to the J35 isolate. The putative NS1
cted with the p6 promoter luciferase reporter constructs shown in the upper part, and
determined and are represented as relative values with the activity of the core promoter
ein used for studying p6 promoter transactivation supports B19V DNA replication. 293
20dNS1 mutant and additionally co-transfected with pHelper and the NS1 expression
sfection were digested with DpnI and subjected to Southern blot analysis with a B19V
ic (RFD) replicative B19V intermediates. (C to F) p6 promoter studies in EA.hy926 cells
). Cells were transfected with the p6 promoter constructs and co-transfected with the
determined and are represented as relative values with the respective activities in the
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56 T. Pozzuto et al. / Virology 411 (2011) 50–64promoter function under physiological virus infection conditions, the
p6 reporter gene cassette was embedded in recombinant AAV (rAAV)
virions. Whereas high-level expression of the B19V p6 promoter has
been demonstrated in a variety of cell lines following plasmid
transfections (Liu et al., 1991; Ponnazhagan et al., 1995), expression
from rAAV-p6-luciferase vectors has been reported to be restricted
mainly to primary human haematopoietic progenitor cells (Srivastava
et al., 1989) and 293 cells (Ponnazhagan et al., 1995). To address the
question of a possible involvement of adenovirus-mediated enhance-
ment of second-strand synthesis, dimeric self-complementary (sc)
AAV vectors were also included in the analysis. These do not depend
upon second-strand DNA-synthesis for gene expression and therefore
exhibit a faster onset and higher absolute levels of gene expression
than conventional AAV vectors with a monomeric genome (McCarty
et al., 2001). In addition to the endothelial cell line EA.hy926, we used
primary endothelial cells from umbilical cord blood (HUVEC) and the
B19V semi-permissive cell line UT7/Epo-S1 to study p6 promoter
activity. A strong increase in reporter gene activity was observed after
super-infection of rAAV-p6-luc transduced EA.hy926 cells with Ad2 at
an MOI of 5 (Fig. 3A and B). Time course experiments showed that, in
comparison to the cells not infected with adenovirus, activation levels
in the range of 10- to 20-fold could bemonitored as early as 16 h post-
infection (p.i.). High activation levels of 362- or 476-fold induction for
themonomeric or dimeric vectors, respectively, were obtained at 40 h
p.i. Whereas the absolute basal activity in the absence of adenovirus
co-infection was about 10-fold higher for the dimeric (sc) vectors
than for the monomeric single-stranded rAAV-p6 vectors, both
showed very similar kinetics and magnitude of adenovirus-induced
transactivation. These results imply that the adenovirus-mediated
increase in reporter gene expression was mostly due to an actual
increase in p6 promoter activity, while a possible enhancement of
second-strand synthesis, as could be taken into account for the single-
stranded monomeric vectors, played only a minor role.
Although the basal activity of the p6 promoter was quite low in
the primary HUVEC, these cells also displayed substantial promoter
transactivation after adenovirus co-infection (Fig. 3C and D). The
onset of adenovirus-mediated promoter induction took place at the
time window around 24 h p.i. and therefore was slightly delayed as
compared to the EA.hy926 cell line, where a clear activation could
already be scored as early as 12 h p.i. (compare Fig. 3C with 3A). In
HUVEC, themaximum levels of transactivation at a time point 48 h p.i.
were 39- and 262-fold for the monomeric and dimeric vectors,
respectively. However, the values obtained for the monomeric vector
may represent an underestimation of the actual degree of transactiva-
tion, since the basal expression levels in the absence of adenovirus co-
infection were in the range of the background luciferase levels of
mock-infected cells. Interestingly, the B19V semi-permissive UT7/
Epo-S1 cells did not show any transactivation of the p6 promoter after
adenovirus co-infection (Fig. 3E and F). Clearly this was not due to a
non-permissiveness of these cells towards transduction with rAAV
vectors, since at least for the dimeric vector, distinct luciferase
activities were measured. Furthermore, control experiments with a
GFP-expressing adenoviral vector showed that under the conditions
applied, more than 50% of the UT7/Epo-S1 cells could be infected with
adenovirus (data not shown).
Identiﬁcation of individual adenoviral functions involved in B19V p6
promoter transactivation in endothelial cells
For a detailed analysis of the adenoviral functions involved in
transactivation of the B19V p6 promoter in endothelial cells, co-
transfection studies with p6-luciferase reporter plasmids were
performed. In initial experiments, a reporter construct harboring the
core p6 promoter region without any upstream regions from the left
ITR (construct p6-luc, Fig. 4A, upper part) was transfected into
EA.hy926 cells followed by super-infection with a replicationcompetent Ad5 vector. A strong activation of reporter gene activity
(26-fold)was observed in comparison to control transfectionswithout
adenovirus infection (Fig. 4A, lower part). The level of transactivation
was distinctively lower than that obtained with the same reporter
cassette in the context of a recombinant AAV vector at an even earlier
time point (48 h versus 40 h, compare Fig. 3A). This may be due to the
high copy number of reporter plasmid molecules taken up by
individual cells during the transfection procedure, thus limiting the
number of cellular and adenoviral transcription factors available for
transactivation at the level of the individual DNA molecules. The
possible involvement of cis-regulatory B19V elements outside of the
core p6 promoter in adenovirus-mediated transactivation was
addressed by the use of two further constructs containing additional
upstream and downstream B19V sequences (Fig. 4A, p6-1-luc and
p6-2-luc). The additional upstreamsequences fromthe left ITR included
the four putative NS1 binding sequences identiﬁed by B19V DNA
replication assays (Guan et al., 2009). The NS1 binding region, which
hadbeen shownearlier tobe essential forNS1-mediated transcriptional
activation of the p6 promoter in the B19Vnon-permissiveHeLa cell line
(Gareus et al., 1998), displayed only very moderate effects on basal p6
promoter activity in the EA.hy926 cells and even distinctly reduced the
level of Ad5-mediated transactivation (Fig. 4A).
In subsequent experiments the exact contribution of individual
early adenoviral functions to p6 promoter transactivation was
examined by co-transfection of p6-luc and p6-2-luc constructs with
different combinations of the Ad5 E1A-13s and E1B functions
expressed under the control of the human cytomegalovirus (HCMV)
immediate early enhancer/promoter and the pHelper plasmid
providing the Ad5 E2a, E4 and VA-RNA functions under their natural
promoters. A possible inﬂuence of the nonstructural B19V NS1 protein
on transactivation was assayed by co-transfection of an HCMV-driven
NS1 construct. To ascertain the functionality of this construct, its
ability to support B19VDNA replication in the non-permissive 293 cell
line in the presence of adenoviral helper functions (E1A, E1B, E2a, E4
and VA-RNA) was monitored. As recently described by Guan et al.
(2009), major amounts of B19V DNA replicative intermediates were
seen in 293 cells after co-transfection of a B19V wildtype genome
(pB19-M20) together with pHelper (Fig. 4B, lane 3). With the NS1-
negative pB19-M20dNS1 construct, B19V DNA replication in the
presence of pHelper was absolutely dependent on complementation
with the HCMV-driven NS1 construct (Fig. 4B, lanes 4 and 5). After co-
expression of NS1, levels of B19V replicative forms were comparable
to those seen with the wildtype B19V plasmid, strongly arguing that
the NS1 expression construct used in the subsequent promoter
studies was fully functional.
In the permanent EA.hy926 cell line, E1A augmented luciferase
activity for both p6 promoter constructs (Fig. 4C and D), although the
level of transactivation (3- to 5-fold) was distinctively lower than that
observed with Ad5 infection. E1B had no effect on p6 activity and the
pHelper plasmid alone displayed only a minor transactivatory effect.
However, in combination with E1A, the pHelper plasmid expressing
E2a, E4 and VA-RNA showed a strong additional transactivation as
compared to cells transfected solely with E1A. In contrast, E1B showed
no or only a minor further stimulation of the activation induced by
E1A, pHelper, or the combination of both plasmids. Very similar
results were obtained for both p6 promoter constructs under
examination, regardless of the presence of the additional up- and
downstream sequences. The expression of NS1 under the control of
the heterologous HCMV promoter had no signiﬁcant effects on the p6
promoter activity in EA.hy926 cells, neither in the absence nor the
presence of adenoviral helper functions. Especially in case of the p6-2
construct this was a rather unexpected ﬁnding, since this construct
harbors the NS1 binding elements described to confer NS1-respon-
siveness to the p6 promoter in other cell lines.
The impact of individual adenoviral functions on B19V p6
promoter activity was studied not only in the permanent cell line
57T. Pozzuto et al. / Virology 411 (2011) 50–64EA.hy926, but also in primary human coronary artery endothelial cells
(HCAEC), which may be of more physiological relevance. An even
stronger cooperative effect between E1A and pHelper-mediated
expression of additional adenoviral functions was observed in these
primary cells (Fig. 4E and F). Whereas transactivation levels of the p6
core promoter with the isolated E1A were below a factor of 10, co-
transfection of both plasmids led to an activation level of more than0
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core promoter construct p6-luc and the indicated E1A expression constructs. All luciferase a
with the activity of the p6 reporter construct in the absence of E1A functions set to 1. The100-fold and even 240-fold after additional co-expression of E1B
(Fig. 4E). A very similar stimulation of p6 promoter activity by the
combined action of E1A and pHelper functions was obtained with the
p6-2-luc construct containing the NS1 binding elements and
sequences downstream from the p6 core promoter (Fig. 4F). As in
the permanent EA.hy926 cell line, the B19V NS1 protein showed no or
only modest effects on p6 activity.0
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cooperative effects with E1A, different combinations of constructs
individually expressing the E2a, the E4orf6 and the VA-RNA functions
were co-transfected with the p6 reporter constructs in EA.hy926 cells,
either in the absence or in the presence of the E1A gene. Stimulation of
the promoter in the absence of the E1A genewas only observed for the
E4orf6 function, although not as pronounced as for the pHelper
plasmid (Fig. 5A and C). Complementation of E4orf6 with E2a and/or
the VA-RNA also did not restore the transactivation levels seen with
pHelper, but even led to minor decrease in the stimulation mediated
by E4orf6 alone. A very similar situation was also observed in the
presence of E1A. Only the E4orf6 function led to a further elevation of
luciferase expression levels (Fig. 5B and D), whereas E2a and the VA-Fig. 6. Induction of B19V capsid expression by individual adenoviral functions. EA.hy926 cel
indicated combinations of adenoviral helper functions. Forty-eight hours post-transfection
E1A or for (C) B19V VP1/2 and NS1 expression. (B) Quantitative representation of the numbe
the mean of four independent wells.RNA had no effect. For the p6-2-luc construct, the E4orf6 could almost
fully substitute for the combined functions of the pHelper plasmid
(Fig. 5D, compare the fourth with the third bar). Although from these
experiments a possible role of E2a and the VA-RNA cannot be ruled
out completely, the E4orf6 seems to be the decisive function
necessary for stimulation of B19V p6 promoter activity in endothelial
cells in cooperation with E1A.
Analysis of the E1A domains involved in p6 promoter activation
demonstrated an absolute requirement for the conserved region 1
(CR3) of the E1A protein, since the effects of the full-length 289 amino
acid protein (E1A-13s) were totally abolished in the E1A-12s
construct missing this domain (Fig. 5E and F). In contrast to CR3,
which mediates the interaction of E1A with components of thels were transfected with SalI linearized pB19-M20 plasmid and co-transfected with the
cells were assayed by immunoﬂuorescence analysis for (A) B19V VP1/2 and adenoviral
r of VP1/2 positive cells in individual wells (2×105 cells per well in total), determined as
Fig. 7. Endothelial EA.hy926 cells support a low level of B19V DNA replication. (A and B)
293 and EA.hy926 cells were transfected with SalI linearized pB19-M20 DNA and
additionally co-transfected with pHelper in case of 293 cells or infectedwith adenovirus
subtypes 2 or 5 in case of EA.hy926 cells. 6 μg ofHirt DNAs isolated 40hpost-transfection
or 48 h post-infectionwere digestedwith (A) 40 units of DpnI for 3 h or (B)with 60 units
of DpnI overnight and subjected to Southern blot analysis with a B19V hybridization
probe. (A) Undigested Hirt DNAs (6 μg) were analyzed in parallel as indicated above the
lanes. (B) As a control for the DpnI digest, 6 μg aliquots of the Hirt DNAs from the
transfection with the control plasmid (lane 3) were spiked with 6 μg of the SalI
linearized pB19-M20 input DNAused in the other transfections and either left untreated
(lane 1/−) or subjected to DpnI restriction under the identical conditions used for the
other Hirt DNAs (lane 2/+). One-sixth of the total restriction digests (corresponding to
1 μg pB19-M20 plus 1 μg Hirt DNA)were then included in the Southern blot analysis. All
the other Hirt DNAs shown in (B) are digested with DpnI. (A and B) Arrows indicate
putative monomeric (RFM) and dimeric (RFD) replicative B19V intermediates.
59T. Pozzuto et al. / Virology 411 (2011) 50–64general transcription machinery, the conserved region 1 (CR1), which
cooperates with CR2 in promoting progression to S phase, was not
required for p6 transactivation (Fig. 5F, E1A-11s).
Isolated adenoviral helper functions stimulate B19V capsid protein
expression
As demonstrated above, E1A in combination with the adenoviral
functions E2a, E4 and VA-RNA expressed from the pHelper plasmid
mediated strong NS1-independent transactivation of the B19V p6
promoter in endothelial cells. To verify whether these combined
adenoviral functions could also promote VP1/2 expression from an
infectious B19 genome, pB19-M20 transfected EA.hy926 cells were
co-transfected with E1A, E1B and pHelper in different combinations.
E1A expression alone was not sufﬁcient to stimulate B19V VP1/2
expression to levels detectable by immunoﬂuorescence analysis, since
only very rare positive cells were scored (Fig. 6B and image not
shown). A higher number of positive cells could be seen after co-
transfection of pHelper (Fig. 6A, ﬁrst panel, and Fig. 6B). In agreement
with the data from the p6 promoter analysis, an even larger number of
VP expressing cells were scored with the combination of pHelper and
E1A (Fig. 6A, second panel, and Fig. 6B). As also could be expected
from the reporter gene analysis, expression of E1B was neither
sufﬁcient nor necessary to induce B19V capsid expression (Fig. 6B).
We also examined the expression of the NS1 protein after co-
transfection of pB19-M20 with adenoviral helper functions. As
already observed after super-infection with adenovirus, we generally
found a higher percentage of cells positive for NS1 than for VP shown
exemplarily for the combination of E1A with pHelper (Fig. 6C). It is
known that VP expression is not exclusively determined at the level of
p6 promoter activity, but can be regulated independently from NS1
expression through differential splicing and polyadenylation (Liu
et al., 1992). In summary, E1A and pHelper exhibited strong
cooperative effects on B19V capsid protein expression, in good
agreement with the results from the p6 reporter gene analysis. Not
quite expectedly, however, the decisive functions in the context of the
complete B19V genome were provided by the pHelper plasmid and
not by E1A.
Endothelial cells support the formation of B19V DNA replication
intermediates
As ﬁrst demonstrated by Guan et al. (2009) and conﬁrmed in our
experiments examining the functionality of the HCMV promoter
driven NS1 protein (Fig. 4B), B19V DNA can be replicated in the non-
permissive 293 cell line in the presence of early adenoviral functions.
With regard to the adenovirus-mediated transactivation of B19V
capsid expression described above, we therefore examined the
possibility that endothelial cells might also support B19V DNA
replication after adenovirus infection. SalI linearized pB19-M20 was
transfected into EA.hy926 cells either in the absence or the presence
of Ad2 and Ad5, respectively. As controls, 293 cells were also
transfected with SalI linearized pB19-M20 and additionally co-
transfectedwith the pHelper plasmid to induce B19V DNA replication.
Hirt preparations of viral DNA, either undigested or digested with
DpnI (Fig. 7A, lanes marked − and + DpnI, respectively), were
subjected to Southern blot analysis with a B19V hybridization probe.
Newly replicated B19V DNA should be resistant to DpnI digestion,
since the enzyme requires methylation at the adenine residues on
both strands of its recognition site for cleavage (unmethylated DNA is
not cut at all and hemimethylated DNA is cut with a 60-fold lower
efﬁciency). In 293 cells, DpnI resistant bands corresponding in size to
the putative monomeric and dimeric replicative B19V DNA inter-
mediates were observed only in the presence of the pHelper plasmid
(Fig. 7A, lane 6), in agreement with the results of Guan et al. (2009). In
EA.hy926 cells, however, a DpnI resistant band at the position of themonomeric intermediate at 5.6 kb was observed already in the
absence of adenoviral helper function (Fig. 7A, lane 8), although
with a lower intensity than the corresponding band in pB19-M20/
pHelper co-transfected 293 cells. The intensity of this band slightly
increased after infection with Ad2 or Ad5 (Fig. 7A, lane 10 and 12). In
addition, a faint band at the position of the putative dimeric
replicative form could be detected. Similar to the 293 cells (Fig. 7A,
lanes 1 and 2), no signal was observed for the EA.hy926 cells without
transfection of pB19-M20 (data not shown), showing the speciﬁcity of
the hybridization probe. To exclude the possibility, that the
appearance of the putative replicative forms in EA.hy926 cells was
due to an incomplete DpnI restriction digest, Hirt DNAs from a second
independent experiment were digested with a larger excess of
enzyme for a prolonged time period and likewise subjected to
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Hirt DNA of the non-transfected control cells was spiked with the
same amount of SalI linearized pB19-M20 DNA and digested with
DpnI under the identical conditions. These controls demonstrated a
complete digest of the excess input DNA (Fig. 7B, lanes 1 and 2). Again
a DpnI resistant band at the position of the putative monomeric
replicative form of B19Vwas observedwith the pB19-M20 transfected
EA.hy926 cells already in the absence of adenovirus infection (Fig. 7B,
lane 6). A weak, but reproducible additional band at about 11 kb
corresponding in size to a B19V dimeric genome could be detected in
the presence of adenovirus (Fig. 7B, lanes 7 and 8). We cannot
unequivocally conclude that the band at 5.6 kb corresponds to fully
replicated B19V DNA, because hemimethylated DNA derived from
second-strand synthesis would also be largely resistant to DpnI
restriction. However, at least second-strand synthesis takes place in
EA.hy926 cells and putative dimeric replicative forms can be seen in
the presence of adenovirus. These ﬁndings strongly indicate that these
endothelial cells can support a low level of B19V DNA replication.
Discussion
Endothelial cells of small intramyocardial arterioles and post-
capillary venules are the target cells for cardiac B19V infections
(Klingel et al., 2004), which have been associated with acute and
chronic forms of myocarditis and dilated cardiomyopathy (DCM)
(Bock, 2006; Bultmann et al., 2003; Kuhl et al., 2005) as well as with
endothelial dysfunction in patients with isolated left ventricular
diastolic dysfunction (Tschope et al., 2005). Mature endothelial cells
have been shown to be non-permissive for B19V, and B19V gene
expression levels are low after experimental infection of endothelial
cells in vitro (Zakrzewska et al., 2005). Although overexpression of
B19V recombinant NS1 protein can disrupt normal endothelial cell
function (Duechting et al., 2008), it is not clear to what extent
expression of B19V gene products during viral persistence in a latent
state may play a role in the development of chronic heart diseases. It
was suggested that speciﬁc conditions or helper factors may
contribute to enhanced B19V infection and replication in endothelial
cells (Zakrzewska et al., 2005).
In DCM patients, B19V DNA is often found in combination with
other viruses, for example, adenoviruses and herpesviruses (Kuhl
et al., 2005). Based on reports demonstrating activation of B19V p6
promoter activity by adenoviral functions (Ponnazhagan et al., 1995)
we hypothesized that adenovirus may act as a helper for B19V
infection in endothelial cells. In line with this hypothesis we could
demonstrate not only an adenovirus-mediated transactivation of
the isolated p6 promoter in endothelial cells, but also a strong
augmentation of the synthesis of B19V proteins in individual B19V
infected or transfected endothelial cells either by super-infection with
adenovirus or by providing the early adenoviral transactivator protein
E1A together with the combined E2a, E4 and VA-RNA functions
expressed by the pHelper plasmid. The close correlation between
stimulation of VP1/2 expression from an infectious B19V genome and
the increase in p6 promoter activity in reporter gene assays suggests
that transcriptional regulation of the only B19V promoter constitutes
at least an important part of the activation mechanism.
The above mentioned earlier study describing transcriptional
stimulation of the isolated p6 promoter by adenoviral functions in the
non-endothelial, but likewise B19V non-permissive KB and 293 cell
lines (Ponnazhagan et al., 1995) identiﬁed E1A not only as necessary,
but for most part also as sufﬁcient for the transactivation. In
endothelial cells we also recognized the E1A gene as an essential
component for adenovirus-mediated transactivation. At variance with
the KB and 293 cell lines examined by Ponnazhagan et al., however,
we observed strong synergistic effects of E1A and the pHelper plasmid
expressing the adenoviral E2a, E4 and VA-RNA functions, especially in
the primary human endothelial cells from the coronary artery.Furthermore, we additionally monitored NS1 and VP1/VP2 protein
expression levels from a complete B19V genome and found that, in
some contrast to the experiments performed with the isolated p6
promoter, the combined pHelper functions even showed a stronger
stimulatory effect than the E1A protein. These results suggest that
transactivation is not exclusively mediated at the level of p6 promoter
activation, but post-transcriptional effects such as transcript proces-
sing and maturation or regulation at the level of translation have also
to be taken into account.
E1A-mediated transactivation of the isolated p6 promoter re-
quired the conserved region 3 (CR3) of the protein. It has been
demonstrated that CR3 very stably interacts with MED23 (Boyer et al.,
1999), a subunit of the human Mediator complex. Through this
interaction, E1A CR3 stimulates the assembly of the RNA polymerase II
preinitiation complex (PIC) (Cantin et al., 2003) and increases the rate
of reinitiation in the presence of sequence-speciﬁc transcription
factors bound to the promoter. Whereas we have not directly studied
the effect of a deletion of the conserved region 2 (CR2), which is
responsible for driving G0 cells into the S phase of the cell cycle (Berk,
2005) by disruption of complexes between the E2F transcription
factor and the Rb family of cell cycle regulators (Raychaudhuri et al.,
1991), the complete abolishment of transactivation after CR3 deletion
in the presence of the entire CR2 strongly suggests that adenovirus-
induced S phase induction plays no major role in the observed
transactivation of B19V gene expression.
The adenoviral promoters driving the expression of E2a, E4orf6 and
the VA-RNA in the pHelper plasmid a least partially rely on E1A
transactivation for activity. Therefore, part of the synergistic effects
observed after co-transfection of E1A and pHelper might be due to the
well-deﬁned role of E1A in the activation of the other early adenoviral
functions (Berk et al., 1979), especially of the E4orf6 gene product,
which in turnmay thenactivate B19Vgeneexpression. Such a cascadeof
adenovirus early function has been described to be required for gene
expression of the helper-dependent AAV-2 parvovirus (Richardson and
Westphal, 1981). A partially indirect effect of E1A in stimulation of B19V
gene expression through induction of other adenoviral functions may
also explain our observation that, after adenovirus super-infection of
B19V infected or pB19-M20 transfected cells, we observed a high
percentage of B19V capsid positive cells, which scored negative for E1A.
Vice versa, especially cells with high E1A expression levels were often
negative for B19VVP1/VP2 expression. Thus, B19Vgeneexpressionmay
be stimulated by the delayed early adenoviral function after E1A
expression has already been shut off through autoregulatory mecha-
nisms (Larsen and Tibbetts, 1987; Smith et al., 1985). Whereas the
promoters driving the expression of the pHelper functions require E1A
for optimum activity, the pHelper plasmid showed some activation of
the isolated p6 promoter and a clear effect on VP1/VP2 expression from
the infectious pB19-M20 plasmid already in the absence of E1A. These
ﬁndings indicate that a low expression level of pHelper functions may
already be sufﬁcient to induce B19V gene expression.
The E4orf6 could not fully substitute for the complete pHelper
plasmid in activation of the p6 promoter. However, it seemed to be
the decisive component, since neither E2a nor VA-RNA showed major
effects, even when combined with the other components. The
decreased activation levels of E4orf6 in comparison to pHelper
could be due the presence of the strong HCMV promoter in the
E4orf6 construct leading to altered expression levels, which might be
too high for optimal p6 stimulation. The gene product of E4orf6 has
been shown to be involved in a variety of activities. Many of these
activities depend upon complex formation with the E1B-55K protein,
such as export of the late adenoviral mRNAs (Babiss et al., 1985;
Leppard and Shenk, 1989) and the mRNAs of the helper-dependent
parvovirus AAV-2 (Samulski and Shenk, 1988) to the cytoplasm. The
E4orf6/E1B-55K complex can also assemble with several cellular
proteins into a Cullin5 based ubiquitin ligase complex, which targets
the tumor suppressor protein p53 and a subunit of the MRN complex
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E1B displayed only marginal additional effects after co-transfection
with pHelper, complex formation of E4orf6 with E1B obviously is not
required for the adenovirus-mediated stimulation of B19V gene
expression. Another activity described for E4orf6 is the induction of
second-strand-synthesis from single-stranded viral genomes, as
demonstrated for the helper-dependent parvovirus AAV (Ferrari
et al., 1996). We have pursued the possibility that adenovirus may
exhibit a similar activity in the context of a single-stranded B19V p6
promoter sequence by comparing the adenovirus-mediated transac-
tivation of a monomeric rAAV-p6 vector, which relies upon second-
strand synthesis for transcription, with that of the corresponding
dimeric vector, which does not. We found no evidence for a major
contribution of the induction of second-strand synthesis to adenovi-
rus-mediated p6 transactivation. Thus, the stimulation of p6-driven
gene expression by the E4orf6 seems to be due to some novel activity
of this protein not thoroughly characterized yet.
Even in the presence of adenoviral factors, detectable B19V capsid
protein expression in endothelial cellswas limited to a very small subset
of cells. Whereas limitations in viral entry, uncoating and conversion of
the single-stranded genome to a transcription-competent double-
stranded formmight account for the small number of VP1/VP2 positive
cells we observed in the initial co-infection experiments, the number of
cells expressing detectable amounts of B19V gene products was not
markedly higher after directly providing the B19V genome in an
intracellular, transcription-competent form by transfection of the
infectious pB19-M20 DNA. Thus endothelial cells seem to lack cellular
factors involved in transcriptional and/or post-transcriptional regula-
tion of B19V gene expression in fully permissive cells and the lack of
these factors can only partially be overcome by supplying adenoviral
functions. Interestingly, no adenovirus-mediated activation of the p6
driven reporter gene supplied as recombinant AAV vector was seen in
the B19V semi-permissive UT7-Epo-S1 cell line. This argues that, in
endothelial cells, adenovirus might modulate some cellular factors,
which are also involved in the restriction of B19V gene expression to
erythroid progenitor cells under physiological conditions.
A key step in generating VP transcripts is replication of the B19V
genome and it has been hypothesized that this process also requires
specialized cellular factors abundantly expressed in EPCs or B19V
semi-permissive cell lines in the presence of Epo (Guan et al., 2009).
Interestingly, already a weak genome replication can lead to a major
increment in the level of transcripts polyadenylated at the distal site
in the B19V genome (Guan et al., 2008). Thus the small increase in the
level of monomeric replicative B19V forms and the appearance of the
barely detectable levels of the putative dimeric forms, which we
observed after adenovirus infection of pB19-M20 transfected endo-
thelial cells, might have major impacts at the level of VP transcript
maturation. It will be of interest to dissect the adenoviral functions
involved in the induction of B19V genome replication in endothelial
cells and directly compare them with the functions required for
stimulation of capsid protein expression.
An essential viral factor required for B19V genome replication is
the NS1 protein and several potential NS1 binding sites in the B19V-
ITRs involved in this activity have been identiﬁed (Guan et al., 2009).
This region containing the NS1 binding sites was also found to be
essential for the replication-independent stimulation of the p6
promoter in a stable HeLa cell after inducible expression of the NS1
protein (Gareus et al., 1998). In contrast to this and earlier ﬁndings in
other non-permissive cells (Doerig et al., 1990), we found no major
activation of a p6 promoter construct harboring the NS1 binding sites
after expression of the NS1 protein from the strong HCMV promoter in
the investigated endothelial cells. Whereas NS1-mediated p6 pro-
moter transactivation may require a critical NS1 concentration range
exceeded by expression of NS1 under control of the heterologous CMV
promoter, endothelial cells may also express only low amounts of
cellular transcription factors such as ATF, NF-κB/c-REl and GC-boxbinding proteins participating in NS1-mediated, replication-indepen-
dent p6 activation (Gareus et al., 1998). After pB19-M20 transfection
of endothelial cells, all VP positive cells were also positive for NS1,
which supports an essential, possibly replication-dependent function
of NS1 in promotion of VP expression in the context of the complete
genome.
Very recently it has been shown that the human embryonal kidney
293 cell line, formerly regarded as non-permissive for B19V, can
support production of infectious B19V progeny virus in the presence
of the pHelper plasmid to levels comparable to those produced in the
semi-permissive megakaryoblastoid cell line UT7/Epo-S1 (Guan et al.,
2009). Whereas in the endothelial cells we could demonstrate both a
strong adenovirus-mediated activation of B19V capsid gene expres-
sion in selected cells and the formation of low levels of putative
replicative B19V DNA intermediates, we have found no clear evidence
yet for the formation of newly synthesized infectious B19V in
endothelial cells (data not shown). In 293 cells co-transfected with
pB19-M20 and pHelper, both the accumulation of replicative B19V
DNA forms and the expression of capsid proteins (data not shown)
were higher than in pB19-M20 transfected EA.hy926 cells expressing
the identical set of adenoviral functions. These ﬁndings might explain
our failure to detect infectious particles in the endothelial cells in vitro.
They do not, however, exclude the possibility that endothelial cells
might support productive B19V replication under specialized condi-
tions in vivo. In line with this argumentation, nucleic acids and both
nonstructural and structural proteins were detected in endothelial
cells from the placenta in a case of intrauterine fetal death caused by
B19V (Pasquinelli et al., 2009).
In the present study we demonstrate for the ﬁrst time that
adenovirus infection can strongly increase low level B19V gene
expression and induce B19V genome replication in endothelial cells.
Although the physiological relevance of the observed B19V transacti-
vation by early adenoviral functions remains to be clariﬁed, our data
clearly reveal that per se B19V gene expression can be activated by
exogenous functions in endothelial cells. Another virus with potential
transactivatory functions, which is frequently found in endomyocar-
dial biopsies from B19V positive patients (Kuhl et al., 2005), is human
herpes virus (HHV6). Since herpesviruses can also act as helpers for a
productive infection of the AAV dependoviruses, future studies ad-
dressing a possible role of HHV-6 early functions in B19V transactiva-
tion seem to be warranted. Induction of B19V gene expression does
not necessarily have to be limited to viral functions. Other non-viral
stressors as for example cytokines representing important mediators
of intra- and intercellular communication could also be involved
therein. A possible contribution of such factors for cardio-endothelial
B19V infections should be the subject of future studies to unravel
possible pathomechanisms.
Materials and methods
Cell lines and primary cells
HEK 293 (human embryonal kidney) cells were cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM, from Gibco BRL,
Karlsruhe, Germany) supplemented with 10%fetal calf serum (FCS,
likewise from Gibco BRL, Karlsruhe, Germany) and 100 μg/ml of
penicillin and streptomycin (Sigma, München, Germany). EA.hy926, a
stable hybrid cell line derived from fusion of primary human umbilical
vein endothelial cells (HUVECs) with the human lung carcinoma cell
line A549, was grown in DMEM supplemented with 10% FCS and
100 μg/ml of penicillin and streptomycin, under HAT (100 mM
hypoxanthine, 0.4 mM aminopterin, 16 mM thymidine) selection
(Invitrogen, Karlsruhe, Germany).
Primary HCAEC (normal human coronary artery endothelial cells)
and HUVEC (normal human umbilical vein endothelial cells) obtained
from PromoCell (Heidelberg, Germany) were cultured according to
62 T. Pozzuto et al. / Virology 411 (2011) 50–64manufacturer's recommendations in endothelial cell growth medium
and endothelial cell growth medium MV2 (PromoCell), respectively.
UT7/Epo-S1 is an erythropoietin (Epo)-dependent cell line origi-
nating from UT7, a megakaryocytic leukemia cell line (Shimomura
et al., 1992), and was kindly provided by Susan Wong (Hematology
Branch, National Heart, Lung, and Blood Institute, National Institutes of
Health, USA). UT7/Epo-S1 cells were cultured in Iscove's modiﬁed
Dulbecco's medium (Mediatech, Herndon, VA) supplemented with
10% FCS, 100 μg/ml of penicillin and streptomycin, 2 mM L-glutamine
(Invitrogen, Karlsruhe, Germany), and 2 units/ml of recombinant
human erythropoetin (EPO, PBL Biomedical Laboratories, USA). All cell
lines and primary cells were cultured at 37 °C with 5% CO2.
Plasmids
The infectious B19V clone pB19-M20 (Zhi et al., 2004) was kindly
provided by K. Brown (Centre for Infections, Health Protection
Agency, UK). The NS1 negative pB19-M20dNS1 construct was
generated by restriction of pB19-M20 with NheI, ﬁll-in reaction and
religation, which created a 4-bp insertion, leading to a frameshift in
the NS1 ORF. Thus only a strongly truncated non-functional NS1
protein of 213 amino acids can be produced.
The p6 promoter construct p6-luc was generated by replacing the
TRE promoter of the plasmid pAd5TRE-luc, which has been described
previously (Fechner et al., 2003), with the p6 core promoter (all
numbering according to the B19V-J35 isolate, GenBank accession no.
AY386330) through PCR ampliﬁcation and ligation via primer-
generated XhoI/BamHI restriction sites. Construct p6-1-luc contains
150 additional nucleotides from the left ITR (nucleotides 231–380),
whereas p6-2-luc contains 196 additional nucleotides from the left
ITR (nucleotides 185–380) and 59 nucleotides from the downstream
NS1 region (nucleotides 616–674). These two plasmids were
constructed by PCR-based ampliﬁcation of the p6 promoter sequences
followed by cloning into MluI- and XhoI-digested pGL3-Basic vector
(Promega).
Plasmid pTR-p6-luc for production of recombinant AAV (rAAV)
harboring the luciferase gene under the control of the B19V p6
promoter was generated by replacing the CMV promoter in the
construct pTR-UF3-luc with B19V nucleotides 381–615 by PCR-based
ampliﬁcation and insertion via KpnI and BamHI restriction sites. The
parental plasmid pTR-UF3-luc originates from pTR-UF3 (Zolotukhin
et al., 1996) and was derived by deletion of the neomycin resistance
gene cassette through partial SalI restriction/religation, deletion of an
additional SalI site by restriction/ﬁll-in reaction and religation,
followed by insertion of an HindIII/XhoI restriction fragment
comprising the luciferase open reading frame (ORF) and the SV40
polyadenylation site from the vector pBL (deWet et al., 1987) into the
HindIII/SalI linearized vector. The construct pD-p6-luc for the
production of self-complementary rAAV vectors was constructed by
ampliﬁcation of a sequence containing the p6 promoter and the
complete luciferase ORF from plasmid p6-luc. Restriction sites KpnI
and SalI for cloning into KpnI/SalI linearized pD-CMV-Red to exchange
the CMV promoter and the RedExpress gene were generated by the
primers used for the ampliﬁcation. pD-CMV-Red is an rAAV packaging
vector with a deletion of the terminal resolution site (TRS) in the left
ITR generated by replacement of the GFP/SV40pA/HSV-TK-Prom/
NeoR cassette in pTR-UF5 (Zolotukhin et al., 1996) with the
RedExpress ORF, followed by deletion of the terminal resolution site
(TRS) in the left ITR by EcoRI and partial MscI restriction, ﬁll-in
reaction and religation.
The pKEX-NS1 construct for expression of the NS1 protein under
control of the human cytomegalovirus early promoter/enhancer
(HCMV) was generated by ampliﬁcation of the complete NS1 ORF
from pB19-M20 with oligonucleotides generating NcoI and XbaI
restriction sites, respectively, followed by intermediate insertion via
these sites into Bluescript SK2 (Stratagene). The NS1 region was thenexcised with NotI and XbaI and inserted into the eukaryotic ex-
pression vector pKEX-XL (Rittner et al., 1991).
Ad5 early function constructs for HCMV-driven expression of Flag-
tagged E1B (CMV-Flag-E1B55K) and E2a (CMV-Flag-E2a) were kind
gifts of David Pintel (University of Missouri, Columbia, USA). Plasmid
CMV-myc-E4orf6 for expression of Myc-tagged E4orf6 and VA
plasmid containing both VAI and VAII were kindly provided by Tom
Shenk (Princeton University, USA). For construction of the plasmids
pcDNA3.1-E1A-13s and pcDNA3.1-E1A-12s, the E1A 13s and the E1A
12s encoding fragments were isolated by BamHI/NheI digestion from
the plasmids pTRE-E1A-13s and pTRE-E1A-12s (Fechner et al., 2003),
respectively, and inserted into the BamHI/XbaI linearized pcDNA3.1
(+) vector (Invitrogen GmbH, Karlsruhe, Germany). The ORF of E1A
11s was synthesized by ATG:biosynthetics GmbH (Merzhausen,
Germany) according to a human adenovirus 5 isolate (GenBank
accession no.: AC 000008) and cloned into the BamHI/XbaI-digested
pcDNA3.1-E1A-13s.
Transfection
Twenty-four hours before transfection, 1×105 of EA.hy926 cells or
2×105 of 293 cells, respectively, were seeded in 24-well plates with
cells reaching a conﬂuence of 70–80% the next day. EA.hy926 cells
were transfected with a total amount of 500 ng DNA by lipofection
using Lipofectamine™ LTX and Plus Reagent (Invitrogen GmbH,
Karlsruhe, Germany) according to the manufacturer's recommenda-
tions after prior change of the growth medium for medium without
serum and antibiotics. Three hours post-transfection, medium was
replaced by complete medium containing FCS, penicillin/streptomy-
cin and HAT.
293 cells were transfected by calcium phosphate precipitation in
24-well plates using a total amount of 1 μg of DNA per well. After 24 h,
cells werewashedwith PBS and incubated at 37 °Cwith freshmedium
for further 24 h.
HCAECs were seeded 24 h before transfection at 5×104 cells per
well in 48-well plates and transfectedwith a total amount of 200 ng of
DNA with Lipofectamine™ LTX and Plus Reagent in medium without
FCS for 3 h according to the instructions of the manufacturer. After
that time period, medium was replaced by fresh growth medium
containing FCS and antibiotics.
Viruses and infection
Parvovirus B19 (B19V) belonging to genotype 1 was puriﬁed from
a patient serum, which was kindly provided by Knut Gubbe (Institute
of Transfusion Medicine and Immunohematology, German Red Cross,
Dresden, Germany). B19V (10 ml) containing serum was bedded on
1 ml of PBS solution containing 20% sucrose (in a frozen state to
facilitate overlay) in ultracentrifuge tubes. Tubes were ﬁlled up with
PBS and samples were centrifuged in a Beckman SW-40 Ti rotor
(Beckman Coulter Inc., Krefeld, Germany) at 100,000×g for 2 h at
4 °C. The virus pellet was diluted in PBS and the concentration of
puriﬁed virus particles was determined by real-time PCR.
Adenovirus type 2 infection (Ad2) was performed with a wildtype
virus, whereas a replication competent adenoviral vector with a
substitution of the E3 region described previously (Fechner et al.,
2000) was used for adenovirus type 5 (Ad5) infection. The replication
deﬁcient adenoviral marker vector Ad5CMVGFP, which harbors
deletions of the E1 and E3 regions, has also been described previously
(Fechner et al., 1999). Viral titers were determined by standard
plaque assays on 293 cells.
Infections with both B19V and adenovirus were performed by
infection of 1 × 105 EA.hy926 or primary endothelial cells in 24-well
plates with 1×104 genome equivalents (GE) per cell of B19V in 300 μl
medium for 24 h, followed by super-infection with Ad2 or Ad5 at an
MOI of 10 in a total volume of 200 μl medium for 2 h. Subsequently
63T. Pozzuto et al. / Virology 411 (2011) 50–64medium was changed and cells were further incubated for the
individual time periods indicated in the ﬁgure legends. Combined
transfection and infection experiments were performed by initial
transfection with the plasmid pB19-M20 for 3 h as described above
followed by infection with Ad2 or Ad5.
The co-infections with recombinant rAAV reporter gene vectors
(1000 genomic particles per cell) and Ad2 (MOI of 5 infectious
particles per cell) were likewise performed in 24-well plates by
simultaneous delivery to 1×105 cells in a total of 200 μl medium
without FCS. After 2 h, medium was changed and the expression of
the luciferase reporter gene was measured at the indicated time
points.
Production of recombinant AAV (rAAV) vectors
Recombinant AAV vectors expressing the luciferase reporter gene
under control of the B19V p6 promoter were packaged and puriﬁed by
iodixanol gradient density centrifugation and afﬁnity chromatogra-
phy on a HiTrap Heparin column (GE Healthcare, Munich, Germany)
according to Zolotukhin et al. (1999, 2002) with only minor
variations. Genomic particles were determined by light-cycler based
real-time PCR using primers binding in the bovine growth hormone
polyadenylation sequence of the packaged p6-luciferase construct
with serial dilutions of the packaged plasmids as standard.
Extraction of viral DNA and Southern blotting
Extraction of viral DNA by a modiﬁed Hirt procedure and Southern
blot analysis were performed as described previously (Weger et al.,
1997). Where indicated, DNA samples were digested with DpnI prior
to electrophoresis. For detection of B19 replicative DNA intermedi-
ates, a 0.94 kb HindIII fragment from the NS1 region encompassing
B19V nucleotides 775–1713 (numbering according to the B19V-J35
isolate) was used. Prehybridization, hybridization and washing
conditions were as described (Weger et al., 1997).
Immunoﬂuorescence
EA.hy926 and 293 cells grown on coverslips in 24-well plates were
ﬁxed and permeabilized with 1 ml of PBS solution containing 4%
formaldehyde and 0.5% Triton X-100. After blocking in TBS buffer with
5% FCS and 0.1% TritonX-100, cellswere incubatedwith anti-B19V-VP1/
2 mouse monoclonal antibody (MAB8293, Millipore, Schwalbach/Ts,
Germany) or anti-B19-NS1 (MAB1424, kindly provided by Susanne
Modrow, Institute of Medical Microbiology and Hygiene, University of
Regensburg, Germany) and anti-E1A (Ad2) rabbit polyclonal antibody
(Santa Cruz Biotechnology, Heidelberg, Germany), all at dilutions of
1:400 in blocking solution, for 1 h. Cells were rinsed and incubatedwith
goat anti-mouse or goat anti-human secondary antibodies Alexa Fluor
594 and goat anti-rabbit secondary antibody Alexa Fluor 488 (Invitro-
gen GmbH, Karlsruhe, Germany), respectively, at a dilution of 1:400 for
45 min. Cover slips were mounted using Dapi-Fluoromount-G™
(Southern Biotechnology Associates Inc., Birmingham, AL, USA).
Fluorescence images were taken with Microscope Leica DMI 4000 B
using the camera Leica DFC 340 FX and the software Leica Application
Suite Version 3.4.0 (Leica Microsystems GmbH, Wetzlar, Germany).
Real-time RT-PCR for VP1/2 transcripts
Total RNA of EA.hy926 cells was isolated with the TRizol® Reagent
(Invitrogen GmbH, Karlsruhe, Germany) according to the manufac-
turer's recommendations. To remove possible residual DNA contam-
inations, 1 μg of total RNA was digested in a ﬁnal volume of 40 μl with
2 units of peqGOLD DNase I (PEQLAB Biotechnologie GmbH, Erlangen,
Germany) according to the manufacturer's recommendations. Re-
verse transcription to generate cDNAs was carried out using the highcapacity cDNA reverse transcription kit (Applied Biosystems, Darm-
stadt, Germany) according to manufacturer's instructions. To exclude
DNA contaminations, two parallel reactions were performed for each
sample, one with and one without reverse transcriptase.
The real-time PCR reactions were performed in a ﬁnal volume of
25 μl containing 50 ng of cDNA, 12.5 μl TaqMan™ Universal PCR
Master Mix, No AmpErase® UNG (Applied Biosystems, Darmstadt,
Germany), 5nMminorgroovebinder (MGB)probe(5′-atgacccagagcacc-3′)
(Applied Biosystems, Darmstadt, Germany), 8 μM forward primer
(5′- cattttcyagacagtttttaatycca-3′, B19V nt 3420–3445) and 8 μM
reverse primer (5′-ctygctgcgggagaaaacac-3′, B19V nt 3489–3470).
All experiments were performed in duplicate on an ABI 7900 HT Fast
real-time PCR System (Applied Biosystems, Darmstadt, Germany).
The real-time PCR was performed under the following conditions:
hot-start denaturation at 95 °C for 10 min, followed by 38 cycles of a
two-step program (denaturation at 95 °C for 15 sec and annealing/
extension at 57 °C for 1 min). Gene expression was normalized to
beta-actin (Applied Biosystems, Kit no. 401970).
Flow cytometry
EA.hy926 cells were detached using 0.25% trypsin–EDTA (Sigma,
Deisenhofen, Germany) and washed with 1× Dulbecco's PBS (PAA,
Pasching, Austria). For ﬁxation, the cells were incubated for 20 min in
500 μl PBS/2% formaldehyde at room temperature (pre-ﬁxation),
washed with PBS and incubated for further 30 min on ice in 90%
methanol/PBS pre-cooled to−20 °C. After blocking in 1 ml of PBS/2%
endobolin for 10 min at room temperature, the cells were pelleted by
centrifugation. Cells were subsequently incubated at room tempera-
ture for 1 h with anti-B19V-VP1/2 mouse monoclonal antibody
(MAB8293, Millipore, Schwalbach/Ts, Germany) at a dilution of
1:200. Cells were washed with 1 ml of PBS and incubated for 45 min
with secondary goat anti-mouse antibody Alexa Fluor 594 (Invitrogen
GmbH, Karlsruhe, Germany) at a dilution of 1:400 at room
temperature in the dark. After washing of the cells with 1 ml PBS
and resuspension in FACS buffer (PBS; 0.5% BSA; 0.1% sodium azide),
approximately 1×105 cells were analyzed by ﬂow cytometry in a
FACS Calibur (Becton Dickinson, Heidelberg, Germany).
Luciferase assay
Fireﬂy luciferase activities of the p6-luciferase reporter plasmids
and the recombinant AAV reporter vectors were measured with the
Bright-Glo™ Luciferase Assay System (Promega GmbH, Mannheim,
Germany) according to the instructions of the manufacturer in a
Lumat LB 9501 luminometer (Berthold Technologies, Bad Wildbad,
Germany).
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